The naltrexone and buprenorphine market size was valued at USD 4.20 billion in 2024 and is expected to reach USD 8.54 billion by 2032, growing at a CAGR of 9.30% over 2025-2032.
Rising prevalence of opioid use disorders globally and higher acceptance of medication-assisted treatment (MAT) programs are driving the naltrexone and buprenorphine market. Increased awareness about opioid dependency, primarily in North America and some Western European countries, is likely to drive healthcare professionals to prescribe naltrexone and buprenorphine on a larger scale.
In April 2024, Indivior rolled out a new digital support program that is connected to buprenorphine treatment, utilizing prescription AI-based adherence tracking, a significant step in the direction of integrating digital health with MAT.
With an estimated 296 million people globally using drugs in 2021 (UNODC), there is an increasing need for treatments for opioid dependence. Additionally, the naltrexone and buprenorphine market growth is being driven by the government initiatives, including wider insurance coverage of MAT (Medicaid in the U.S.) and payment schemes. Meanwhile, drug manufacturers are upping R&D spending, in part to develop long-acting injectables and combo products that improve compliance and effectiveness. For instance, Indivior and Alkermes are major naltrexone and buprenorphine manufacturers that emphasize innovation and availability.
For instance, regulatory backing, FDA authorizations for extended-release buprenorphine (Sublocade), and injectable naltrexone (Vivitrol), also contribute to the naltrexone buprenorphine market share by enhancing treatment adherence. On the supply side, expanded manufacturing facilities and funding by national drug control programs to reduce the treatment gap, coupled with a rise in spending on behavioral healthcare and telemedicine to improve patient access, have been driving naltrexone and buprenorphine market growth globally. This swirling mix of demand, regulatory push, and changing therapeutic modalities is projected to continue to capture naltrexone and buprenorphine market analysis results.
In 2023, Alkermes revealed expanded clinical studies for Vivitrol (naltrexone) in conjunction with cognitive behavioral therapy (CBT) in hopes of further boosting the recovery rates, and a key phenomenon in the integrated care models and the naltrexone and buprenorphine market trends.
Market Dynamics:
Drivers:
Expanding Access to Treatment and Technological Advancements Boosting Adoption for Naltrexone and Buprenorphine Market
Growing access to naltrexone and buprenorphine globally, heightened government support, and advancements in drug delivery devices are factors driving the naltrexone and buprenorphine markets. The number of people with opioid use disorder (OUD), totaling >60 million globally, is one main driving force behind the increase in demand for medication-assisted therapies.
Government commitments to address the opioid crisis are significant. For instance, in 2023, Congress appropriated USD 4.8 billion to support treatment programs and increased MAT access through SAMHSA. Furthermore, the development of technologies, such as long-acting depot injections and subdermal implants, has led to enhanced patient compliance with a low risk of relapse, in turn stimulating the growth of the naltrexone and buprenorphine market.
Braeburn Pharmaceuticals and others are developing long-acting formulations for buprenorphine, including Brixadi, currently approved for weekly and monthly dosing by the FDA in 2023. Furthermore, simplified regulatory routes and revised standards, including the elimination of the X-waiver requirement for buprenorphine prescribing in the U.S., are expanding the pool of licensed prescribers. Integration of telehealth after COVID-19 has increased access to MAT, particularly in rural areas with limited resources, thereby enhancing overall global naltrexone and buprenorphine market analysis.
Restraints:
Stigma, Regulatory Barriers, and Limited Access Hamper Market Expansion
Several restraints are still impacting the naltrexone and buprenorphine market, despite an increasing demand. One significant barrier is MAT (medication-assisted treatment) related stigma, which restricts reach, even among individuals who have been diagnosed. Even if the 1.0:2.41 ratio is sufficient, only 11% of individuals in need of MAT received it in 2022, based on the National Survey on Drug Use and Health (NSDUH), indicating a substantial treatment penetration deficit. Further, limited provider infrastructure and shortage of MAT-trained physicians in low- and middle-income countries (LMICs) limit global scalability of treatment. Regulatory limitations, particularly in areas with rigid narcotic regulating laws, are dampening the market analysis of Maltrexone and Buprenorphine.
In many European countries, for instance, restrictive buprenorphine prescription practices keep access extremely low despite increasing demand. Furthermore, supply-side issues, such as the manufacture of depot or implantable formulations, are expensive and could delay the deployment. LMICs have a low level of spending on R&D, and the markets in such countries are imbalanced. Pharmaceutical companies are also under legal scrutiny, and for instance, Indivior paid more than USD 600 million in 2020 to settle charges related to marketing, which raised red flags with regulators. Finally, attitudes of people with substance use disorder regarding side effects, withdrawal treatment, and the stigmatization of MAT as “replacing one drug with another” further obstruct treatment acceptance, despite the unambiguous clinical advantages, which, in turn, limits the market share potential for naltrexone and buprenorphine in some areas and with some populations.
By Product
Buprenorphine accounted for 73.53% revenue share in the global market in 2024. This dominance is largely attributable to its superior effectiveness for the treatment of opioid use disorder (OUD), its reduced abuse potential owing to partial agonism, and multiple available formulations. Buprenorphine’s diverse route of administration, including oral, injectable, and implantable formulations, renders it well suited for treatment in clinical and outpatient contexts.
Meanwhile, the naltrexone segment is expected to be the fastest expanding, fueled by growing penetration for the treatment of alcohol use disorder (AUD) and increasing demand for long-acting injectable format, which can enhance patient adherence.
By Route of Administration
Based on the route of administration, the injectable buprenorphine segment dominated the market with a share of 68.14% in 2024. Rising preference for depot injections that decrease dosage frequency and increase compliance, particularly amongst the high-risk pool, has enhanced the growth of this segment.
The oral naltrexone segment, on its part, is estimated to register the highest CAGR since it is largely prescribed as compared to the implants on account of convenience and price, and will capture 55.14% of the naltrexone market share by 2024.
By Application
Concerning the application, OUD was the major indication in both drug segments, with OUD contributing 69.52% revenue share in the naltrexone segment in 2024. The increase in opioid addiction and the initiation of national support programs for medication-assisted treatment (MAT) have increased its application.
Alcohol use disorder in the naltrexone space is also set to grow rapidly in the future, with heightened disease diagnosis and treatment guidelines changing to reflect the efficacy of naltrexone to reduce alcohol relapse.
By Distribution Channel
In terms of distribution channels, hospital pharmacies contributed to the largest market share of 47.93% in 2024, owing to controlled treatment protocols and easy access to monitored care for high-risk OUD patients.
Retail pharmacies are likely to have the fastest growth, driven by regulatory changes expanding access to outpatient MAT and greater prescribing of oral agents for chronic relapse prevention.
The North American naltrexone and buprenorphine market led the market in 2024, due to the high prevalence of opioid use disorder (OUD), large numbers of government initiatives, and easy availability of medication-assisted treatments (MAT).
The U.S. naltrexone and buprenorphine market size was valued at USD 1.30 billion in 2024 and is expected to reach USD 2.48 billion by 2032, growing at a CAGR of 8.44% over 2025-2032. In the U.S., the regional market is handled primarily by the U.S. market, which is mainly dominated by well-established reimbursement support, treatment protocols, and changes in policy, such as the removal of the X-waiver to prescribe buprenorphine.
By 2023, more than 2.1 million U.S. residents were diagnosed with OUD, indicating substantial demand for treatment. Combine this with strategic investments made in harm-reduction programmes, and the market uptake of long-acting injectable drugs like Sublocade and Brixadi increased. Canada is the fastest-growing country in the region due to MAT implementation and favorable country policies for opioid agony therapy (OAT). The proliferation of telehealth delivery models for addiction care is also making treatment more available in rural and underserved populations, in both the U.S. and Canada.
Europe is the second biggest and ever-changing market with increasing opioid dependence and the unification of MAT in the public healthcare system, and harm-reduction policies. The U.K. is the first-ranking state owing to its advanced drug policies, wide free availability of drug treatment in the form of the NHS, and widespread use of buprenorphine treatment. Opioid related deaths represented just under 49% of drug misuse deaths as of 2023, which serves to highlight the importance of effective treatments. Germany is the fastest-growing MAT market in Europe, owing to its recent regulatory changes leading to ease of access to MAT and a rapidly increasing number of opioid addicted patients. Moreover, countries such as France and Spain are increasing the government-sponsored addiction centers, which are likely to support regional growth. An increasing number of pharmaceutical R&D activities into extended-release naltrexone across Europe are also one of the factors that are driving the growth of the naltrexone and buprenorphine market in the region.
The Asia Pacific market is poised for the fastest growth, with a rising number of opioid abuse incidences, government-led awareness programs, and investment in mental health infrastructure. This region is made up of India, which averages the highest utilization, driven by a large population of people with opioid dependence, which numbers more than 2 million, as per the Ministry of Social Justice & Empowerment. The naltrexone and buprenorphine market growth has been driven by an increasing number of de-addiction centers, government initiatives funded through programs, such as Nasha Mukt Bharat Abhiyaan, and the low price of generic buprenorphine.
China and Australia have also played a significant role, with China using OAT programmes and Australia using its extensive health infrastructure to introduce more recent MAT methods. Japan is growing at a steady pace owing to the rise of clinical research and government support for new formulations. Telemedicine-based addiction care and public–private partnerships, in addition to ethnic vendors, will continue enhancing treatment accessibility in APAC, thereby continuing to fuel the naltrexone and buprenorphine market growth.
Leading naltrexone and buprenorphine companies operating in the market include Indivior PLC, Collegium Pharmaceutical (BioDelivery Sciences International, Inc.), Alkermes, Inc., Orexo US, Inc., Titan Pharmaceuticals, Omeros Corporation, Camurus, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals, and Dr. Reddy’s Laboratories.
In February 2025, the FDA approved crucial label updates for SUBLOCADE (buprenorphine extended-release), including a rapid initiation protocol (treatment can begin just one hour after transmucosal buprenorphine) and authorization for additional injection sites (thigh, buttock, arm), enhancing flexibility, convenience, and patient adherence.
In January 2025, Delpor Inc. progressed into Phase 3 near-ready design for a titanium-based implant capable of delivering naltrexone for up to one year. Backed by NIH HEAL funding, this long-duration implant promises enhanced compliance and reversibility, ideal for both opioid and alcohol use disorders.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 4.20 billion |
| Market Size by 2032 | USD 8.54 billion |
| CAGR | CAGR of 9.30% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Naltrexone, Buprenorphine (BELBUCA, Sublocade, Suboxone, Zubsolv, and Others) • By Route of Administration (Naltrexone, (Oral Administration, Injectable Administration, and Implantable Administration), Buprenorphine (Oral Administration, Injectable Administration, and Implantable Administration) • By Application (Naltrexone, (Opioid use disorder (OUD), Alcohol use disorder (AUD))), Buprenorphine (Opioid use disorder (OUD)) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Indivior PLC, Collegium Pharmaceutical (BioDelivery Sciences International, Inc.), Alkermes, Inc., Orexo US, Inc., Titan Pharmaceuticals, Omeros Corporation, Camurus, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals, and Dr. Reddy’s Laboratories. |
Ans: The Naltrexone and Buprenorphine market is anticipated to grow at a CAGR of 9.30% from 2025 to 2032.
Ans: The market is expected to reach USD 8.54 billion by 2032, increasing from USD 4.20 billion in 2024.
Ans: Growing access to naltrexone and buprenorphine globally, heightened government support, and advancements in drug delivery devices are factors driving the naltrexone and buprenorphine market.
Ans: One significant barrier is MAT (medication-assisted treatment) related stigma, which restricts reach, even among individuals who have been diagnosed.
Ans: North America dominated the Naltrexone and Buprenorphine market.
Table Of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Opioid Use Disorder (2024), by Region
5.2 Prescription Trends of Naltrexone and Buprenorphine (2024), by Region
5.3 Patient Access and Therapy Initiation Rates (2021–2032)
5.4 Healthcare Spending on OUD Treatment, by Region (Government, Commercial, Private, Out-of-Pocket), 2024
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Naltrexone And Buprenorphine Market Segmentation By Product
7.1 Chapter Overview
7.2 Naltrexone
7.2.1 Naltrexone Market Trends Analysis (2021-2032)
7.2.2 Naltrexone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Buprenorphine
7.3.1 Buprenorphine Market Trends Analysis (2021-2032)
7.3.2 Buprenorphine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 BELBUCA
7.3.3.1 BELBUCA Market Trends Analysis (2021-2032)
7.3.3.2 BELBUCA Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Sublocade
7.3.4.1 Sublocade Market Trends Analysis (2021-2032)
7.3.4.2 Sublocade Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5 Suboxone
7.3.5.1 Suboxone Market Trends Analysis (2021-2032)
7.3.5.2 Suboxone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.6 Zubsolv
7.3.6.1 Zubsolv Market Trends Analysis (2021-2032)
7.3.6.2 Zubsolv Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.7 Others
7.3.7.1 Others Market Trends Analysis (2021-2032)
7.3.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Naltrexone And Buprenorphine Market Segmentation By Route of Administration
8.1 Chapter Overview
8.2 Naltrexone
8.2.1 Naltrexone Market Trends Analysis (2021-2032)
8.2.2 Naltrexone Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.3 Oral Administration
8.2.3.1 Oral Administration Market Trends Analysis (2021-2032)
8.2.3.2 Oral Administration Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.4 Injectable Administration
8.2.4.1 Injectable Administration Market Trends Analysis (2021-2032)
8.2.4.2 Injectable Administration Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.5 Implantable Administration
8.2.5.1 Implantable Administration Market Trends Analysis (2021-2032)
8.2.5.2 Implantable Administration Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Buprenorphine
8.3.1 Buprenorphine Market Trends Analysis (2021-2032)
8.3.2 Buprenorphine Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.3 Oral Administration
8.3.3.1 Oral Administration Market Trends Analysis (2021-2032)
8.3.3.2 Oral Administration Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.4 Injectable Administration
8.3.4.1 Injectable Administration Market Trends Analysis (2021-2032)
8.3.4.2 Injectable Administration Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.5 Implantable Administration
8.3.5.1 Implantable Administration Market Trends Analysis (2021-2032)
8.3.5.2 Implantable Administration Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Naltrexone And Buprenorphine Market Segmentation By Application
9.1 Chapter Overview
9.2 Naltrexone
9.2.1 Naltrexone Market Trends Analysis (2021-2032)
9.2.2 Naltrexone Market Size Estimates and Forecasts to 2032 (USD Billion)
9.2.3 Opioid Use Disorder (OUD)
9.2.3.1 Opioid Use Disorder (OUD) Market Trends Analysis (2021-2032)
9.2.3.2 Opioid Use Disorder (OUD) Market Size Estimates and Forecasts to 2032 (USD Billion)
9.2.4 Alcohol Use Disorder (AUD)
9.2.4.1 Alcohol Use Disorder (AUD) Market Trends Analysis (2021-2032)
9.2.4.2 Alcohol Use Disorder (AUD) Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Buprenorphine
9.3.1 Buprenorphine Market Trends Analysis (2021-2032)
9.3.2 Buprenorphine Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3.3 Opioid Use Disorder (OUD)
9.3.3.1 Opioid Use Disorder (OUD) Market Trends Analysis (2021-2032)
9.3.3.2 Opioid Use Disorder (OUD) Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Naltrexone And Buprenorphine Market Segmentation by Distribution Channel
10.1 Chapter Overview
10.2 Hospital Pharmacies
10.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
10.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Retail Pharmacies
10.3.1 Retail Pharmacies Market Trend Analysis (2021-2032)
10.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Others
10.4.1 Others Market Trends Analysis (2021-2032)
10.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Naltrexone And Buprenorphine Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.2.3 North America Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.2.4 North America Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.2.5 North America Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.2.6 North America Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.2.7.2 USA Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.2.7.3 USA Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.2.7.4 USA Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.2.8.2 Canada Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.2.8.3 Canada Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.2.8.4 Canada Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.2.9.2 Mexico Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.2.9.3 Mexico Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.2.9.4 Mexico Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Europe Naltrexone And Buprenorphine Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.3.3 Europe Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.4 Europe Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.5 Europe Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.6 Europe Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.7 Germany
11.3.7.1 Germany Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.7.2 Germany Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.7.3 Germany Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.7.4 Germany Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.8 France
11.3.8.1 France Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.8.2 France Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.8.3 France Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.8.4 France Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.9 UK
11.3.9.1 UK Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.9.2 UK Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.9.3 UK Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.9.4 UK Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.10 Italy
11.3.10.1 Italy Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.10.2 Italy Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.10.3 Italy Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.10.4 Italy Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.11 Spain
11.3.11.1 Spain Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.11.2 Spain Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.11.3 Spain Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.11.4 Spain Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.12 Poland
11.3.12.1 Poland Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.12.2 Poland Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.12.3 Poland Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.12.4 Poland Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.13 Turkey
11.3.13.1 Turkey Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.13.2 Turkey Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.13.3 Turkey Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.13.4 Turkey Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.14 Rest of Europe
11.3.14.1 Rest of Europe Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.14.2 Rest of Europe Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.14.3 Rest of Europe Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.3.14.4 Rest of Europe Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.4.3 Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.4 Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.5 Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.6 Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.7 China
11.4.7.1 China Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.7.2 China Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.7.3 China Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.7.4 China Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.8 India
11.4.8.1 India Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.8.2 India Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.8.3 India Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.8.4 India Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.9.2 Japan Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.9.3 Japan Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.9.4 Japan Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.10.2 South Korea Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.10.3 South Korea Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.10.4 South Korea Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.11 Singapore
11.4.11.1 Singapore Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.11.2 Singapore Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.11.3 Singapore Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.11.4 Singapore Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.12 Australia
11.4.12.1 Australia Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.12.2 Australia Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.12.3 Australia Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.12.4 Australia Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.13 Rest of Asia Pacific
11.4.13.1 Rest of Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.13.2 Rest of Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.13.3 Rest of Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.4.13.4 Rest of Asia Pacific Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Trend Analysis
11.5.2 Middle East and Africa Naltrexone And Buprenorphine Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.5.3 Middle East and Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.4 Middle East and Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.5 Middle East and Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.6 Middle East and Africa Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.7 UAE
11.5.7.1 UAE Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.7.2 UAE Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.7.3 UAE Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.7.4 UAE Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.8 Saudi Arabia
11.5.8.1 Saudi Arabia Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.8.2 Saudi Arabia Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.8.3 Saudi Arabia Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.8.4 Saudi Arabia Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.9 Qatar
11.5.9.1 Qatar Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.9.2 Qatar Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.9.3 Qatar Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.1.9.4 Qatar Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.10 South Africa
11.5.10.1 South Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.10.2 South Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.10.3 South Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.10.4 South Africa Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.11 Rest of Middle East & Africa
11.5.11.1 Rest of Middle East & Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.11.2 Rest of Middle East & Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.11.3 Rest of Middle East & Africa Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.5.11.4 Rest of Middle East & Africa Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.6.3 Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.6.4 Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.6.5 Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.6.6 Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.6.7.2 Brazil Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.6.7.3 Brazil Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.6.7.4 Brazil Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.6.8.2 Argentina Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.6.8.3 Argentina Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.6.8.4 Argentina Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.6.9 Rest of Latin America
11.6.9.1 Rest of Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.6.9.2 Rest of Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.6.9.3 Rest of Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
11.6.9.4 Rest of Latin America Naltrexone And Buprenorphine Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
12. Company Profiles
12.1 Indivior PLC
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Alkermes, Inc.
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Orexo US, Inc.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Titan Pharmaceuticals
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Omeros Corporation
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Camurus
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Sun Pharmaceutical Industries Ltd.
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Teva Pharmaceuticals
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Dr. Reddy’s Laboratories
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
Naltrexone
Buprenorphine
BELBUCA
Sublocade
Suboxone
Zubsolv
Others
By Route of Administration
Naltrexone
Oral Administration
Injectable Administration
Implantable Administration
Buprenorphine
Oral Administration
Injectable Administration
Implantable Administration
By Application
Naltrexone
Opioid use disorder (OUD)
Alcohol use disorder (AUD)
Buprenorphine
Opioid use disorder (OUD)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players